Results 1 to 10 of about 1,073 (146)

甲状腺相关眼病的EUGOGO临床分级特征 [PDF]

open access: yesZhongshan Daxue xuebao. Yixue kexue ban, 2018
【目的】分析甲状腺相关眼病(GO)以欧洲甲状腺相关眼眶病专家组(EUGOGO)标准分级的临床特 征。【方法】回顾性收集2010年1月-2016年12月于中山大学孙逸仙纪念医院内分泌与眼科明确诊断为GO的 110例病例,记录其病史、眼部检查,分别按照EUGOGO标准、NOSPECS标准进行GO严重程度的分级,按照临床 活动度评分(CAS)进行GO炎症活动度的分级,并对这些指标进行综合性分析。【结果】本研究共收集110例患 者211眼。患者年龄平均47.4(S=12.8)岁,其中具有吸烟史27例 ...
范淑贤   +4 more
doaj   +1 more source

Hypo vs. hyperthyroid eye disease: is there any difference?

open access: yesBMC Ophthalmology, 2023
Background Thyroid-eye disease (TED) is the most common extra-thyroidal presentation of graves’ disease. We performed this study to compare clinical characteristics of TED in hypothyroid vs. hyperthyroid patients.
Bahram Eshraghi   +3 more
doaj   +1 more source

Association of clinical course with thyroid-stimulating immunoglobulin in Graves' ophthalmopathy in Mongolians.

open access: yesPLoS ONE, 2022
Graves' ophthalmopathy (GO) is a complex inflammatory condition affecting the orbit and is often associated with Graves' disease (GD). This study aims to determine the levels of thyroid-stimulating immunoglobulin (TSI) and thyroid-stimulating hormone ...
Oyungerel Bayarmunkh   +5 more
doaj   +1 more source

Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy

open access: yesThyroid Research, 2019
Background Treatment of moderate to severe Graves’ orbitopathy (GO) is based mainly on intravenous pulses of methylprednisolone. High doses of methylprednisolone can exert several adverse effects, some of which might be life-threatening. The objective of
Dorota Walasik-Szemplińska   +2 more
doaj   +1 more source

The association of race with thyroid eye disease presentation and outcomes

open access: yesFrontiers in Ophthalmology
IntroductionClassification of thyroid eye disease (TED) is largely based on guidelines developed in Europe and North America. Few studies have investigated the presentation and treatment of TED in Black populations.
Diane Wang   +15 more
doaj   +1 more source

Severity of thyroid eye disease and type-2 diabetes mellitus: Is there a correlation?

open access: yesIndian Journal of Ophthalmology, 2020
Purpose: To study the correlation between thyroid eye disease (TED) with type-2 diabetes mellitus. Methods: A cross-sectional cohort study was conducted from Jan 2018 to Dec 2018, in patients presenting with thyroid eye disease to orbit and oculoplasty ...
Lakshmi B Ramamurthy   +5 more
doaj   +1 more source

The clinical tomographic interconnection in diplopia of patients with Graves' orbitopathy

open access: yesКлиническая и экспериментальная тиреоидология, 2012
There was investigated the relationship between the clinical features of the diplopia in patients with the Graves’ orbitopathy and the specific signs of the orbit obtained by the multi-slice CT scanning in the study.

doaj   +1 more source

Sight-Threatening Condition in Severe Thyroid Eye Disease: How We Should Manage

open access: yesActa Medica Indonesiana, 2022
Thyroid eye disease (TED) is an autoimmune disorder that is associated with thyroid gland dysfunction which causes muscle and orbital fat enlargement.
Yunia Irawati   +5 more
doaj  

Oftalmopatía de Graves. Diagnóstico, evaluación y tratamiento

open access: yesRevista Mexicana de Endocrinología, Metabolismo y Nutrición
La oftalmopatía u orbitopatía de Graves (OG) es un trastorno autoinmune e inflamatorio (prevalencia 30 a 50% en enfermedad de Graves), caracterizada por inflamación de los tejidos orbitarios y protrusión ocular, debido a involucro de las células Th1 y ...
Fernando Bolaños-Gil de Montes   +1 more
doaj   +1 more source

Diagnosis, Follow-Up and Treatment Results in Thyroid Ophthalmopathy

open access: yesTürk Oftalmoloji Dergisi, 2015
Objectives: To discuss our follow-up and treatment results in thyroid-associated ophthalmopathy (TAO). Materials and Methods: The records of 168 TAO cases who were followed at our clinic between October 1998 and October 2013 were reviewed ...
Esra Savku, Kaan Gündüz
doaj   +1 more source

Home - About - Disclaimer - Privacy